- 2 次围观
产品图片
货号/SKU
NR-15786
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质,其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类:美国、3
产品描述信息
NR-15786??Mycobacterium tuberculosis, CDC1551, Transposon Mutant Knock-Out Pool 14(Mutant Bacteria)|Mycobacterium tuberculosis|CDC1551, Transposon Mutant Knock-Out Pool 14|-60°C or colder|WR BishaiAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain CDC1551, Transposon Mutant Knock-Out Pool 14, NR-15786."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
In 2002, TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of Mycobacterium tuberculosis (M. tuberculosis). In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized.
There are 20 transposon mutant knock-out pools available from BEI Resources (NR-15773 to NR-15792) that are companion products to the DeADMAn DNA Microarray (available from BEI Resources as NR-18958). The DeADMAn DNA Microarray is used for identification of genes essential for the survival of a stress condition in an in vivo model system infection.
M. tuberculosis, strain CDC1551 transposon mutant knock-out pool 14 is reported to be a mixture of 20 genetically defined M. tuberculosis transposon mutants. Some of the transposon mutants in knock-out pool 14 are available individually (see Pool 14 components below).
Each vial contains approximately 1 mL of bacterial culture in Middlebrook 7H9 broth with OADC enrichment containing 100 ?g/mL cycloheximide and 20 ?g/mL kanamycin.
Components:
In 2002, TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of Mycobacterium tuberculosis (M. tuberculosis). In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized.
There are 20 transposon mutant knock-out pools available from BEI Resources (NR-15773 to NR-15792) that are companion products to the DeADMAn DNA Microarray (available from BEI Resources as NR-18958). The DeADMAn DNA Microarray is used for identification of genes essential for the survival of a stress condition in an in vivo model system infection.
M. tuberculosis, strain CDC1551 transposon mutant knock-out pool 14 is reported to be a mixture of 20 genetically defined M. tuberculosis transposon mutants. Some of the transposon mutants in knock-out pool 14 are available individually (see Pool 14 components below).
Each vial contains approximately 1 mL of bacterial culture in Middlebrook 7H9 broth with OADC enrichment containing 100 ?g/mL cycloheximide and 20 ?g/mL kanamycin.
Components:
Description of Transposon Knock-Out Mutant | Strain CDC1551 Gene | Strain H37Rv Gene1 | BEI Resources Product Number2 |
---|---|---|---|
HYPOTHETICAL PROTEIN | MT1558 | Rv1510 | NA |
CONSERVED HYPOTHETICAL PROTEIN | MT0977 | Rv0950c | NA |
PROBABLE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN C | MT3194 | Rv3111 | NR-18250 |
POSSIBLE METHYLTRANSFERASE | MT0223 | Rv0213c | NR-15089 |
CONSERVED HYPOTHETICAL PROTEIN | MT2120 | Rv2061c | NR-18256 |
CRISPR-ASSOCIATED PROTEIN | MT2887 | Rv2820c | NR-18257 |
PROBABLE EXCINUCLEASE ABC | MT1669 | Rv1633 | NR-15091 |
PROBABLE ENDONUCLEASE | MT3396 | Rv3297 | NR-18396 |
CONSERVED HYPOTHETICAL PROTEIN | MT1073 | Rv1043c | NA |
PROBABLE AMIDOHYDROLASE (AMINOHYDROLASE) | MT3405 | Rv3306c | NR-18402 |
HYPOTHETICAL PROTEIN | MT2960 | Rv* | NA |
PROBABLE CONSERVED ATP-BINDING PROTEIN, ABC TRANSPORTER | MT3290 | Rv3197 | NA |
PROBABLE INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE | MT3518 | Rv3410c | NA |
CONSERVED HYPOTHETICAL PROTEIN | MT0691 | Rv0662c | NA |
HYPOTHETICAL PROTEIN | MT2030 | Rv1978 | NA |
PROBABLE DRUG-TRANSPORTER TRANSMEMBRANE ATP-BINDING PROTEIN | MT1390 | Rv1348 | NR-17594 |
PROBABLE TRANSPOSASE FUSION PROTEIN | MT3430 | Rv3327 | NA |
POSSIBLE OXIDOREDUCTASE | MT3849 | Rv3741c | NA |
CONSERVED HYPOTHETICAL PROTEIN | MT0609 | Rv0580c | NA |
CONSERVED HYPOTHETICAL PROTEIN | MT3895 | Rv3787c | NA |
1Rv*- In some cases there is no M. tuberculosis, strain H37Rv homologue to the M. tuberculosis, strain CDC1551 gene | |||
2NA- Individual transposon mutant not available from BEI Resources but may be available from TARGET |
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.在此限制上订单将在发货前发送到北欧批准. 目标(结核病形成动物研究和基因评估任务性,以使使用定义的方案和测试分枝杆菌的定义突变体(M.Tuberculosis)的定义突变体来实现多种动物物种中的人结核病建模.除了动物建模活动外,还创建和表征了一种腺体转座子突变体. 有来自BEI资源(NR-15773至NR-15792)的20名转座突变体敲除池产品到Deadman DNA微阵列(可从BEI资源获得NR-18958).死亡DNA微阵列用于鉴定在体内体内系统感染中的胁迫条件的生存基因所必需的基因. m.结核病,菌株CDC1551转座子突变突出池14被据报道为20种遗传定义的 m的混合物.结核病转座突变体.敲除池14中的一些转座子突变体可单独使用(参见下面的池14个组分). 每个小瓶在中间体中含有大约1ml的细菌培养物,其中包含100μg/ ml环己酰胺的OADC富集和20μg/ ml kanamycin. .customtable {border:0px;单元填充:5px;细胞间距:5px;}.定制TD,TH {边框:0PX;垂直对齐:底部;}#col1 {text-align:left;宽度:70%;}#col2 {text-align:center;宽度:10%;}#col3 {text-align:center;宽度:10%;}#col4 {text-align:center;宽度:10%;} 转座子敲除突变体的描述 菌株 cdc1551 基因 菌株 基因 1 bei资源产品 2 假设蛋白 mt1558 RV1510 NA 保守假设蛋白 MT0977 RV0950C NA 可能的钼辅因子生物合成蛋白C mt3194 rv3111 nr-18250 可能的甲基转移酶 mt0223 rv0213c nr-15089 保守假设蛋白 mt2120 rv2061c nr-18256 CRISPR相关蛋白 mt2887 rv2820c >nr-18257 可能的excinuclease abc mt1669 RV1633 nr-15091 可能的内切核酸酶 mt3396 RV3297 保守假设蛋白 mt1073 rv1043c na 可能的氨基水解酶(氨基水解酶)(氨基水解酶) MT3405 RV3306C nr-18402 假设蛋白 mt2960 RV * na 可能保守的ATP结合蛋白,ABC转运蛋白 MT3290 RV3197 NA 可能inosine-5'-单磷酸脱氢酶 mt3518 Rv3410c na 保守假设蛋白 mt0 691 rv0662c na 假设蛋白 mt2030 rv1978 na 可能的药物转运蛋白跨膜ATP结合蛋白 MT1390 RV1348 nr-17594 可能转座酶融合蛋白 mt3430 RV3327 na 可能的氧化还原酶 mt3849 RV3741C NA 保守假设蛋白 mt0609 rv0580c na 保守假设蛋白 mt3895 Rv3787c na 1 rv * - 在某些情况下,没有 M.结核病,菌株H37RV同源物至 m.结核病,菌株CDC1551基因 2 na - 从BEI资源不提供的单个转座子突变体,但可以从 target
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2021-12-21
2024-01-21
2021-12-21
2022-04-01
2021-12-21
2020-06-09
2024-05-19
2020-08-04
2022-04-01
2022-04-01
2024-08-16
2022-04-01
2022-01-10
2021-12-21
2022-04-01
2022-04-01